In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hutchison MediPharma Ltd.

Division of Hutchison China MediTech Ltd.
www.hmplglobal.com

Latest From Hutchison MediPharma Ltd.

Oncology Dominates As China Drug, Biologic Approvals Surge

China saw a 150% increase in new drug approval applications in 2018, with oncology taking the lion's share of investigational new drug filings, notes a newly released annual report from China’s Center for Drug Evaluation. Meanwhile Darzalex has become the latest foreign drug to be approved.

China Approvals

China’s Asieris Bets On Bladder Cancer With Rediscovered Asset From Johns Hopkins

Emerging Company Profile: Aiming to change the current practice of surgically removing the bladder, China Asieris hopes to use an older drug to treat early-onset bladder cancer. This is the fourth and last in a series of China-based Emerging Company Profiles.

China Cancer

Divest, Refocus, Transition: Multinationals Embark On Uncharted Path In China

Facing unprecedented pricing pressures in China, multinationals are embarking on a major shift away from mature products to focus more on innovative drugs, but there are major challenges linked to the transition that won’t be easy to navigate, notes a new report.

China Business Strategies

Choose Carefully For China Drug Development Success: White Paper

By avoiding crowded space and focusing instead on therapeutic areas with large potential, China remains attractive for drug developers, notes a recent white paper from investment bank China E-Capital.

China Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Hutchison China MediTech Ltd.
  • Senior Management
  • Christian Hogg, Interim CEO
    Weiguo Su, PhD, EVP, Drug Research
    Mark Lee, VP, Corp. Fin. & Dev.
    May Wang, SVP, Bus. Dev. & Strategic Alliances
  • Contact Info
  • Hutchison MediPharma Ltd.
    Phone: (86) 20 5079 0088
    Bldg. 4, 720 Cai Lun Rd.
    ZJ Hi-Tech Park
    Shanghai, 201203
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register